The price paid for the specialist maker of diabetes drugs is far from cheap but with obesity continuing to rise, the potential is significant

The chief's departure signals a shift in strategic direction for which investors should be happy but they should not expect instant solutions

Investors yet to be convinced of chief's plan to turn round the defence contractor following huge losses and ethics inquiries at its companies